PharmaMar reports OS data from Phase III of Aplidin for MM

PharmaMar S.A. (Madrid:PHM) reported data for the secondary overall survival (OS) endpoint from the Phase III ADMYRE trial in 255 patients with relapsed or refractory multiple myeloma (MM) evaluating Aplidin plitidepsin plus dexamethasone vs. dexamethasone alone. Aplidin plus dexamethasone

Read the full 398 word article

User Sign In